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Methods: The sample was from the Einstein Aging Study. The estimated glomerular filtration rate
(eGFR, calculated in mL/min/1.73 m2 units) was classified into low (,45), moderate (45–59), and
high (60). Separate binary logistic regression models were run to determine if eGFR is associated
with amnestic MCI (aMCI) and dysexecutive MCI (dMCI).
Results: Of 622 eligible participants 65 (10.5%) had low eGFR, 43 (7.1%) had aMCI, and 46 (7.6)
had dMCI. Low eGFR was independently associated with dMCI and aMCI in fully adjusted models.
Conclusion: At cross-section low eGFR is associated with a higher risk of both dMCI and aMCI. eGFR
may contribute to the development of these cognitive states directly. Alternatively, low eGFR may be a
marker for risk factors that influenceboth thekidneyand thebrain, suchas coronarymicrovascular disease.
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Chronic kidney disease (CKD) has a well-established as-
sociation with impairment on neurocognitive tests, particu-
larly measures of frontal/executive function [1–4]. In a
systematically recruited sample of older adults from the
Einstein Aging Study we examined three cognitive
domains derived from a principal components analysis of
13 neurocognitive tests. The domains included general
ability, executive function, and episodic memory. Our
results showed an association between low estimated
glomerular filtration rate (eGFR) and the executive
function composite composed of four tests, including Trailthor. Tel.: 718-430-3886; Fax: 718-430-3817.
chard.lipton@einstein.yu.edu
16/j.dadm.2014.12.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).Making Tests A and B [5], Digit Symbol Coding [6], and
Block Design [6] and two of the four individual tests [7].
Although CKD has been associated with cognitive status
and decline in older adults it has rarely been investigated in
relation to clinically significant cognitive states, such as mild
cognitive impairment (MCI) or dementia.MCI is a transitional
state between normative cognitive aging and dementia [8].
MCI is often divided into amnestic (aMCI) form,with reduced
memory performance and nonamnestic forms (naMCI), with
reduced performance in cognitive domains other thanmemory
[8]. Recent work has highlighted the potential importance of a
subtype of naMCI with predominant impairment in executive
function [9]. This condition, known as dysexecutive MCI has
been defined as objective memory impairment in an executive
function composite characterized as 1.5 standard deviations
lower than that of a normative sample [9].
Studies by Post et al. [10] and Griva et al. [11] have intro-
duced the concept of MCI in CKD and hemodialysis (HD)imer’s Association. This is an open access article under the CC BY-NC-ND
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tients—24 persons with CKD and 27 persons on HD, and
found that 39 (76%) had some form of MCI. aMCI occurred
in 20% of the CKD group and in 29% of the HD group; non-
amnestic MCI occurred in 80% of the CKD group and in
71% of the HD group were classified as naMCI. In Griva
et al.’s study on 145 dialysis patients, the authors found
that up to 67.5% of participants were cognitively impaired,
as defined by performance 1 standard deviation (SD) lower
than the mean on two or more of five neuropsychological
tests. The authors did not distinguish between aMCI and
naMCI, thus participants may have impairments in more
than one cognitive domain. Results showed that 49% of par-
ticipants had executive function impairment (as indicated by
Trails B) and 49% had verbal memory impairment (as
measured by Rey Auditory Verbal Learning Test).
Many studies of cognitive function and kidney disease are
limited by modest sample sizes [10–12] and by the selection
of patients based from referral populations with CKD and
HD [1,10,11,13,14]. Furthermore, Griva et al. did not
distinguish between MCI subtypes; although, studies
continually show an association between the executive
component of cognitive function and memory [7,10,11].
Thus research on MCI in decreased renal function
[10,11,15] usually adopts a patient population diagnosed
with CKD or end-stage renal disease (ESRD), or are
receiving hemodialysis to investigate dementia or MCI
[1,10,11,13,14]. Many individuals with CKD, or decreased
eGFR, are community-dwelling elderly; however, there are
few studies that investigate eGFR and dementia in
community-dwelling samples [16], and there are no studies
to our knowledge that have investigated MCI and kidney
function in representative community-based samples.
Determining if MCI is present in community-dwelling
elderly with decreased eGFR will help in determining if
MCI develops before the individual begins treatment at
renal clinics. Identifying cognitive impairment early on in
the course of any potential CKD developments may result
in fewer complications and allow for longer independent
living, and subsequently less hospitalizations. It will
benefit the individual if practitioners are aware that
noncompliance may be due to imminent MCI states rather
than negligence.
In this analysis we adopted a cross-sectional design to
explore the association between eGFR andMCI, specifically
aMCI and a subcomponent of naMCI known as dysexecutive
MCI (dMCI) [9,16,17]. dMCI reflects executive dysfunction
and is treated as a clinical subtype in many studies [9,18].
Our aims were to determine whether an association exists
between low eGFR and aMCI and/or dMCI. Based on our
prior work [7], in which an association was found between
eGFR and the executive function composite, but not between
eGFR and the episodic memory composite, we anticipated
an independent association between eGFR and dMCI; how-
ever, we did not hypothesize an association between eGFR
and aMCI.2. Methods
This analysis was cross-sectional and was conducted
within a subset of the Einstein Aging Study (EAS) cohort.
EAS enrolls community-dwelling, English-speaking resi-
dents of Bronx county in New York who are 70 years or
older. Participants were systematically recruited from the
Health Care Financing Administration/Centers for Medicaid
and Medicare Services rosters for Medicare-eligible persons
who were 70 years or older between 1993 and 2004, and
from New York City Board of Elections from 2004 onward.
Individuals are first mailed introductory letters about the
study and research assistants then followed up by phoning
to obtain oral consent and administer a brief screening inter-
view. Participants then come in for “Day 1” where the neu-
ropsychological battery, the clinical interview and a physical
examination are administered to them. After this they are
scheduled for “Day 2”, which takes place within 2 weeks af-
ter the first visit; here we collect blood and urine samples of
the participants and administer experimental cognitive tests.
Thus, the administration of the neuropsychological battery
and the blood collection of the participants are done within
a 2-week period. In the EAS participants are excluded if
they have visual and/or auditory impairments that interfere
with neuropsychological testing, psychiatric symptom-
atology that interferes with test completion, or a nonambula-
tory status. Written informed consent is obtained on their
first clinical visit (Katz et al., 2012). The study protocol
was approved by the local institutional review board. Indi-
viduals with dementia at baseline status for eGFR were
excluded from these analyses. Baseline status here refers
to the first wave of data for which participants have eGFR
data.
2.1. Assessment of estimated glomerular filtration rate
We estimated eGFR in mL/min/1.73 m2 using the modi-
fication of diet in renal disease [19] formula:
eGFR5186!Serum Creatinine1:154!Age0:203
!½1:210 if Black!½0:742 if Female
This eGFR formula has been recommended for older peo-
ple [20]. We treated eGFR in predefined categories in units
of mL/min/1.73 m2 as low (,45), moderate (45–59), and
high (60). This is an often used cut-off in studies on renal
function and cognition [2,4,21]. Furthermore, older adults
with an eGFR lower than 45 mL/min/1.73 m2 are at
increased risk for progression of CKD to ESRD and other
adverse outcomes than patients with eGFR more than
60 mL/min/1.73 m2.
2.2. Diagnosis of aMCI
Participants were diagnosed with aMCI according to up-
dated criteria [22], which required that objective memory
impairment in the memory domain be defined as 1.5 SDs
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or a score of 24 or less on the Free and Cured Selective
Recall Test [24], subjective memory impairment indicated
by self or significant other (self: the Consortium to Establish
a Registry for Alzheimer’s Disease [CERAD] assessment
[25], other: CERAD or IQ CODE [26]), absence of func-
tional decline (based on self or significant other’s report or
as indicated by the Independent Activities of Daily Living
[IADLs] Lawton Brody Scale [27]), and not clinically diag-
nosed with dementia.
2.3. Classification of dMCI
Individuals were classified as dMCI if they were impaired
at 1.5 SDs lower than the age-adjusted mean of the sample
on at least one of the following four executive function tests:
Digit Symbol Coding [6], Block Design [6], Trail Making
Test A, and Trail Making Test B [5]. This classification is
based on our previous work [7] in which these four tests
comprised the executive function composite in a principal
components analysis based on a battery of 13 neurocognitive
tests administered in the EAS. A similar approach to
defining dMCI was also taken in previous studies [9].
aMCI and naMCI are different subtypes of cognitive
impairment, one primarily characterized by memory
impairment, and the other reflects impairment in domains
of language, executive function, attention, and speed. In
this article we only explored the dysexecutive component
of naMCI, thus aMCI and dMCI remained independent
components of MCI. Also when investigating aMCI and
dMCI individually, we excluded any cases that may have
had comorbid aMCI and dMCI to allow for “pure” sub-
types to be studied individually. Thus, the aMCI subtype
only consisted of individuals with aMCI but no dMCI,
and the dMCI subtype only consisted of individuals with
dMCI but no aMCI. In this study we did not explore other
subtypes of naMCI. aMCI and dMCI were mutually exclu-
sive. Individuals with aMCI and individuals with dMCI
were compared with the rest of the sample, i.e. individuals
without any aMCI, dMCI or both, referred to here as no
aMCI and no dMCI.
Baseline characteristics were examined according to (1)
eGFR category, and (2) aMCI/dMCI/no aMCI and no dMCI.
2.4. Descriptive characteristics and covariates
Descriptive characteristics and covariates included infor-
mation on demographics, vascular conditions, anemia, body
mass index (BMI), mood and APOE ε4, a genetic marker for
risk of Alzheimer’s disease. Vascular indicators were repre-
sented by a cardiovascular disease (CVD) morbidity sum-
mary measure composed of the sum of presence of
hypertension, diagnosis of diabetes, a history of myocardial
infarction, and a history of stroke. Mood variables included
the geriatrics depression scale [28] (GDS, range 0–15, with 6
scores or more indicating depression). This information was
obtained via the clinical interview which included questionson medical history, medications, and health behavior [29].
The APOE ε4 gene, known for its risk for Alzheimer’s
disease, was obtained from the whole blood, or was isolated
from buffy coat that had been stored at 270C using
the Puregene DNA Purification System (Gentra System,
Minneapolis, MN). Genotyping was performed using a
Pyrosequencing PSQ HS 96A system (http://www.
pyrosequencing.com).
2.5. Statistical analysis
The mean 6 SD of continuous variables was compared
using analysis of variance for characteristics according to
eGFR category, and MCI status. Categorical variables
were compared using the c2 and presented in percentages.
We then used binary logistic regression to assess the asso-
ciation between eGFR category and cognitive status sepa-
rately for aMCI, and for dMCI. In the models we adjusted
for descriptive variables that significantly distinguished
among participant groups of eGFR and cognitive status.
Analyses were performed using the Statistical Package
for the Social Sciences (SPSS, version 22.0, SPSS Inc., Chi-
cago, IL, USA).3. Results
3.1. Descriptive characteristics3.1.1. Characteristics by eGFR
Table 1 summarizes descriptive characteristics by eGFR
category for the 622 qualified participants. The mean age
of the sample was 79.7 years and 60.6% were female. Over-
all mean eGFR was 68.4 mL/min/1.73 m2. As eGFR
increased from low to moderate and high, mean age
decreased (82.0 vs. 80.0 and 79.2) as did mean GDS (2.7
vs. 2.2 and 2.0). Years of education increased with eGFR
group (13.0 vs. 14.3 and 14.2). There was also a significantly
higher frequency of individuals with CVD comorbidity
(96.9% and 87.6% and 64.4%) in the low eGFR group
than in the moderate or high groups.
3.1.2. Characteristics of aMCI, dMCI vs. no aMCI or dMCI
Table 2 shows the characteristics of the sample divided
into participants with aMCI, dMCI, and no aMCI and no
dMCI. Of the 622 participants 517 had neither dMCI nor
aMCI. There were 43 (7.1%) participants with aMCI but
not dMCI and 46 (7.6%) participants with dMCI but not
aMCI. There were 16 participants that had both aMCI and
dMCI; these were excluded from our main analysis as they
met the criteria for dementia with the exception of functional
decline.
Results showed that participants with aMCI and dMCI
were significantly older than individuals without either dis-
order (82.6 and 81.4 vs. 79.2 years). Individuals with
aMCI scored higher on the GDS than individuals with
dMCI and those free of these conditions (3.1 vs. 2.0 and
Table 1
Baseline characteristics of the sample according to renal function category defined by eGFR (standard deviations in brackets unless otherwise stated as % for
categorical variables)
Total eGFR, ,45 eGFR, 45–59 eGFR, 60
Pn 5 622 n 5 65 (10.5%) n 5 144 (23.2%) n 5 413 (66.4%)
eGFR mean 68.4 (18.9) 36.4 (7.2) 53.3 (3.7) 78.7 (13.4) .000
Demographics
Age 79.7 (5.5) 82.0 (6.2) 80.0 (5.4) 79.2 (5.4) .001
Females (%) 377 (60.6) 37 (56.9) 101 (70.1) 239 (57.9) .028
Caucasian 429 (69.0) 43 (66.2) 92 (63.9) 294 (71.2) .232
Education, yrs 14.1 (3.5) 13.0 (3.4) 14.3 (3.4) 14.2 (3.5) .022
Vascular variables
Anemia (%) 85 (13.7) 9 (13.8) 27 (18.8) 49 (11.9) .117
CVD morbidity (%) 448 (72.0) 63 (96.9) 119 (82.6) 266 (64.4) .000
Past smokers (%) 331 (53.5) 41 (63.1) 74 (51.4) 216 (52.7) .517
Smokers (%) 27 (8.2) 3 (7.5) 7 (9.6) 17 (7.8) .878
BMI 27.3 (4.8) 26.8 (4.6) 28.0 (5.2) 27.2 (4.7) .128
Mood
GDS 2.12 (2.04) 2.7 (2.3) 2.2 (2.2) 2.0 (2.0) .023
Genes
APOE ε4 (%) 127 (23.6) 17 (13.4) 26 (20.5) 84 (23.4) .399
Abbreviations: eGFR, estimated glomerular filtration rate; CVD morbidity, cerebrovascular disease morbidity; BMI, body mass index; GDS, Geriatric
Depression Scale; APOE ε4, apolipoprotein E allele e4.
NOTE. Individuals with dementia have been excluded.
NOTE. All percentages are column percentages. This includes history of myocardial infarction, history of stroke, diagnosis of diabetes, and hypertension. The
Pearson’s chi-square was used for categorical variables.
Table 2
Characteristics of the whole sample divided in according to no aMCI or
dMCI, with aMCI, and with dMCI (standard deviations in brackets unless
otherwise stated as % for categorical variables)
No aMCI or dMCI aMCI dMCI
PN 5 517 (85.3) N 5 43 (7.1) N 5 46 (7.6)
Age, mean
(6SD)
79.2 (5.3) 82.6 (5.9) 81.4 (6.00) .000
Females (%) 315 (60.9) 15 (32.6) 31 (67.4) .107
Caucasian (%) 369 (71.4) 29 (63.0) 17 (23.0) .000
Years in education 14.4 (3.4) 14.0 (3.0) 11.8 (4.2) .000
eGFR, mean
(6SD)
69.7 (18.2) 63.4 (23.2) 59.7 (19.3) .000
Low eGFR 40 (7.7) 10 (23.3) 13 (28.3) .000
Moderate eGFR 118 (22.8) 11 (25.6) 10 (21.7)
High eGFR 359 (69.4) 22 (51.2) 23 (50.0)
Anemia (%) 73 (14.1) 2 (4.7) 8 (17.4) .223
CVD morbidity
(%)
361 (69.8) 32 (74.4) 42 (91.3) .008
Past smokers (%) 280 (54.5) 22 (51.2) 21 (45.7) .801
Current smokers
(%)
25 (8.9) 0 2 (9.5) .340
BMI 27.4 (4.8) 26.8 (5.3) 27.7 (4.8) .692
GDS 2.0 (2.01) 3.1 (2.4) 2.0 (1.6) .002
APOE ε4 carriers
(%)
100 (22.2) 10 (28.6) 13 (33.3) .202
Abbreviations: aMCI, amnestic mild cognitive impairment; dMCI, dys-
executiveMCI; eGFR, estimated glomerular filtration rate; SD, standard de-
viation; CVD morbidity, cerebrovascular disease morbidity; BMI, body
mass index; GDS, Geriatric Depression Scale; APOE ε4, apolipoprotein E
allele e4.
NOTE. Dementia cases have been excluded.
NOTE. All percentages are column percentages. This includes the history
of myocardial infarction, history of stroke, diagnosis of diabetes, and hyper-
tension. The Pearson’s Chi-square was used for categorical variables.
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dMCI (28.3%) belonged to the low eGFR group than indi-
viduals with aMCI (23.3%) and neither aMCI nor dMCI
condition (7.7%).
3.2. Probabilistic analysis
Variables that significantly differentiated among the
groups included basic demographic characteristics, CVD
morbidity, and GDS. We included these as covariates in
the binary logistic models. We also included APOE ε4
because of its association with Alzheimer’s disease, which
is thought to be a precursor of aMCI [30].
3.2.1. eGFR and aMCI
Results from the binary logistic regression for aMCI
(Table 3) showed that low eGFR (as opposed to high) was
associated with aMCI after adjusting for GDS (odds ratio
[OR] 5 2.88, 95% confidence interval [CI] 5 1.20–6.92,
P 5 .018; Model 1), CVD morbidity (OR 5 3.19,
CI 5 1.30–7.82, P 5 .011; Model 2), and APEOe4
(OR5 3.42, CI5 1.34–8.77, P5 .010; Model 3). eGFR re-
mained significant even after simultaneously adjusting for
all three covariates (GDS, CVD comorbidity, and APEOe4)
(OR 5 3.04, CI 5 1.11–8.33, P 5 .031; Model 4). There
were no differences between the moderate and the high
groups. Furthermore, for every increased year of age the
odds of having a classification of aMCI was 1.07
(CI 5 1.00–1.14) independent of GDS score, CVD
morbidity, and APOE ε4. For every added point on the
GDS, the odds of having aMCI was 1.21 (CI 5 1.05–
1.40), independent of the eGFR and CVD morbidity.
Table 3
Odds ratios for aMCI diagnosis as defined by eGFR group membership
aMCI
Model 1 Model 2 Model 3 Model 4
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 1.10* (1.04–1.17) 1.10** (1.04–1.17) 1.07* (1.00–1.14) 1.07 (1.00–1.14)
Sex (M) 1.79 (0.92–3.49) 1.69 (0.88–3.25) 1.98 (0.96–4.06) 2.09* (1.00–4.37)
Education 1.00 (0.91–1.11) 0.99 (0.90–1.09) 0.96 (0.86–1.07) 0.97 (0.87–1.09)
Caucasian 1.16 (0.52–2.60) 1.27 (0.57–2.81) 1.06 (0.46–2.40) 1.02 (0.44–2.35)
eGFR (low) 2.88* (1.20–6.92) 3.19* (1.30–7.82) 3.42** (1.34–8.77) 3.04* (1.1–8.33)
eGFR (moderate) 1.45 (0.66–3.18) 1.57 (0.72–3.45) 1.73 (0.74–4.04) 1.67 (0.69–4.06)
GDS 1.22* (1.07–1.39) – – 1.21** (1.05–1.40)
CVD morbidity – 1.03 (0.48–2.22) – 1.02 (0.42–2.50)
APOE ε4 – – 1.61 (0.73–3.58) 1.86 (0.82–4.21)
Abbreviations: aMCI, amnestic mild cognitive impairment; dMCI, dysexecutive MCI; GDS, Geriatric Depression Scale; CVD morbidity, cerebrovascular
disease morbidity; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; APOE ε4, apolipoprotein E allele e4.
NOTE. Low eGFR 5 ,60 mL/min/1.73 m2, moderate eGFR 5 45–59 mL/min/1.73 m2, high eGFR 5 60 mL/min/1.73 m2. This includes history of
myocardial infarction, history of stroke, diagnosis of diabetes, and hypertension. Model 1 was adjusted for age, sex, education, race, and GDS. Model 2
was adjusted for age, sex, education, race, and GDS and CVD morbidity. Model 3 was adjusted for age, sex, education, race, GDS, and APOE ε4. Model 4
was adjusted for age, sex, education, race, GDS, CVD morbidity, and APOE ε4. The high eGFR group was the reference group.
*P , .05.
**P , .01.
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Table 4 shows the results from the binary logistic regres-
sion for dMCI. Low eGFR (as opposed to high) was associ-
ated with higher odds of developing dMCI independent of
GDS (OR 5 4.30, CI 5 1.89–9.81, P 5 .001; Model 1);
CVD morbidity (OR 5 3.21, CI 5 1.40–7.35, P 5 .006;
Model 2); APEOe4 (OR 5 4.88, CI 5 2.04–11.71,
P 5 .000; Model 3); and GDS, CVD, and APEOe4 together
(OR 5 4.18, CI 5 1.67–10.44, P 5 .002; Model 4). There
were no differences between the moderate and the high
groups. Increasing age, less years in education, and not being
Caucasian were also associated with higher odds of devel-
oping dMCI independent of eGFR, GDS, CVD comorbidity,
and APEOe4 in all four models. In Model 4, for every added
year in life the odds of dMCI were 1.08 (CI 5 1.02–1.15);
and for every added year of formal education the odds
were 0.86 (CI5 0.77–0.95). Last, if the individual is Cauca-
sian, the odds of developing executive dysfunction were 0.26
(CI5 0.51–3.07) independent of GDS, CVD morbidity, and
APEOe4.4. Discussion
In this cross-sectional study, we explored aMCI and dMCI
in relation to eGFR in a sample of community-dwelling older
adults. aMCI is widely considered a pre-Alzheimer’s disease
state; whereas dMCI is a subcomponent, or a more specific
area of naMCI reflecting executive dysfunction, and typi-
cally associated with vascular dementia (VaD) [9].
This is the first report of eGFR relating tomemory impair-
ment and executive dysfunction in community-dwelling
elderly in the absence of dementia. Our results showed inde-
pendent associations between dMCI and decreased eGFR,
and aMCI and eGFR as opposed to high eGFR. These resultsyield some discussion. We anticipated and found a strong as-
sociation between dMCI and decreased eGFR; our results
showed an OR of 4.18 (CI 5 1.67–10.44). In our previous
work [7] we found an association between poor eGFR and
poor scores on the executive function composite developed
from four neurocognitive tests (Trail Making tests A and B,
Digit Symbol, and Block Design). These results were also
supported by an earlier study that found high prevalence of
naMCI (more than 70%), but not aMCI, in CKD and HD
dementia-free patients [10]. Previous research on CKD and
cognitive function has also depicted impairment in tests
measuring attention and executive function [1,2,14]. Thus,
our first results supported our hypothesis of an independent
association between dMCI and decreased eGFR.
We did not anticipate an association between aMCI and
decreased eGFR. Our previous work and previous research
do not consistently show an association between neurocog-
nitive function tests measuring memory, aMCI, or Alz-
heimer’s disease and decreased eGFR or CKD. Although
studies report associations between neurocognitive memory
measures and decreased eGFR [2,3,31] results vary from
study to study. For example, in Yaffe et al. [14] decreased
eGFR (defined as ,30 mL/min/1.73 m2) was associated
with delayed memory, but not with category fluency, which
is a measure of semantic memory; whereas in Kurella et al.
[2] decreased eGFR (also defined as ,30 mL/min/1.73 m2)
was associated with both delayed memory and category
fluency. Similarly, in prevalence studies, executive dysfunc-
tion, naMCI and VaD seem to be more prevalent in CKD
than are memory impairment, aMCI, or Alzheimer’s disease,
with prevalence rates going up as high as 32% for executive
dysfunction vs 24% for memory impairment [12], 80% for
naMCI vs. 20% for aMCI [10], and annual declines in
eGFR being associated with higher risk of VaD (relative
Table 4
Odds ratios for dMCI as defined by eGFR group membership
dMCI
Model 1 Model 2 Model 3 Model 4
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 1.07* (1.01–1.14) 1.08** (1.02–1.15) 1.08* (1.02–1.14) 1.08* (1.02–1.15)
Sex (male) 0.98 (0.49–2.01) 0.95 (0.47–1.94) 1.01 (0.49–2.02) 1.01 (0.47–2.20)
Education 0.83*** (0.75–0.92) 0.84*** (0.76–0.92) 0.83*** (0.76–0.92) 0.86** (0.77–0.95)
Caucasian 0.24*** (0.12–0.48) 0.25*** (0.13–0.50) 0.24*** (0.12–0.47) 0.26*** (0.12–0.54)
eGFR (low) 4.30*** (1.89–9.81) 3.21** (1.40–7.35) 4.88*** (2.04–11.71) 4.18** (1.67–10.44)
eGFR (moderate) 1.25 (0.55–2.85) 1.11 (0.48–2.53) 1.43 (0.59–3.46) 1.26 (0.51–3.07)
GDS 0.96 (0.80–1.13) – – 0.99 (0.83–1.18)
CVD morbidity – 3.05* (1.01–9.22) – 0.42 (0.14–1.31)
APOE ε4 – – 1.75 (0.79–0.87) 1.86 (0.83–4.16)
Abbreviations: dMCI, dysexecutive MCI; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval; GDS, Geriatrics Depression
Scale; CVD morbidity, cerebrovascular disease morbidity; APOE ε4, apolipoprotein E allele e4.
NOTE. Low eGFR5,60 mL/min/1.73 m2 moderate eGFR5 45–59 mL/min/1.73 m2 high eGFR560 mL/min/1.73 m2. This includes history of myocar-
dial infarction, history of stroke, diagnosis of diabetes, and hypertension. Model 1 was adjusted for age, sex, education, and race. Model 2 was adjusted for age,
sex, education, race, and CVDmorbidity. Model 3 was adjusted for age, sex, education, race, and APOE ε4. Model 4 was adjusted for age, sex, education, race,
CVD morbidity, and APOE ε4. The high eGFR group was the reference group.
*P , .05.
**P , .01.
***P , .001.
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AD (RR 5 1.29, 95% CI 5 0.68–2.43, P 5 .432) [13,21].
One explanation for our association between decreased
eGFR and aMCI could be that decreased eGFRmay actually
lead to aMCI. For example, poor kidney function may lead to
metabolic abnormalities which interfere with brain function.
Second, eGFRmay be amarker for vascular or other risk fac-
tors that are associated with neural dysfunction and poor
cognitive performance. Although AD and VaD are distin-
guished, the conditions often occur together in the same indi-
vidual. Vascular pathology may unmask AD pathology
leading to earlier or more prominent cognitive dysfunction.
In addition, vascular disease with its associated hypoperfu-
sion may lead to accelerated accumulation of beta amyloid
and ultimately to higher rates of cognitive decline [32,33].
We excluded individuals with both aMCI and dMCI from
the primary analysis. eGFR was associated with the co-
occurrence of aMCI and dMCI independent of CVD
morbidity and APOE ε4; however, the GDS attenuated this
association (OR 5 2.42, CI 5 0.83–7.07) (Supplementary
Table 1). This showed that the GDS is associated with
both eGFR and comorbid aMCI and dMCI. The attenuated
association between low eGFR and aMCI once the GDS is
entered into the model may also show that depression is a
stronger associate of comorbid aMCI and dMCI than
eGFR. However, this association is difficult to interpret
and may indicate that aMCI may precede kidney impair-
ment; thus although eGFR may not play a role in the onset
of aMCI per se, it may trigger its development, and a quick
succession of AD or mixed dementia may follow rapidly.
Our results lend support to two hypotheses: (1) the
shared environmental risk factor hypothesis in which an
underlying vascular mechanism is affecting both the kidneyand the brain, and (2) the unidirectional casual hypothesis
where vascular toxins because of decreased kidney func-
tion affect cognition. Both of these hypotheses lead to
eventual cognitive decline, which may develop into VaD,
AD, or mixed AD. Given that eGFR is a vascular marker
affecting bodily function, including the brain, and that
cognitive function is a marker of brain integrity and
possibly cognitive reserve, it is safe to speculate that
both these mechanisms affect each other and are affected
by several potential risk factors.
The results of this study are important in several ways:
First, our results demonstrate that MCI together with
decreased eGFR, possibly without a CKD diagnosis, is pre-
sent long before individuals are receiving treatment or have
received a diagnosis for CKD. Second, our results also
show that MCI together with decreased eGFR is not always
specifically targeted to executive function but rather seems
to extend to memory function as well. Last, correlations do
not imply causation, and much speculation may surround
the associations found in this study. Decreased eGFR already
hints at signs of disease; the possibilities of how eGFR may
affect or be affected by cognition are broad, ranging from
common underlying mechanisms to eGFR causing or trig-
gering MCI, to even initial poor cognition or MCI leading
to poor compliance of medication escalating to poorer prog-
nosis. This knowledge provides further insight into the nature
of cognitive impairment in possibly early or pre-CKD devel-
opment, and attention should be thwarted toward identifying
and minimizing risk-factors. It is still the case that a strong
association is present between decreased eGFR and MCI in
community-dwelling elderly. In the general population, in-
dividuals with MCI are also 5 to 10 times more likely to
develop dementia (Petersen et al., 2001). Interventions in
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impairment would have a major impact on public health
[34]. Methods that may detect early CVD risk and compli-
cations may not only avoid morbidity and disease, but also
halt or delay the onset of cognitive impairment. Unrecog-
nized dMCI may result in an inability to address fully ac-
tivities of daily living such as planning meals, taking care
of finances, following any medication regiments, keeping
or following up appointments, and following directions.
Thus, the importance of developing awareness among prac-
titioners may not only help in targeting these individuals
and identify underlying problems but will also help in
improving the quality of life of these individuals and
may eventually decrease frequency of hospitalizations.
The strengths of the sample include the ethnically diverse
group of participants, thewide range of variables available to
study the MCIs, medical and psychological variables, and
the relatively large sample available to studyMCI and poten-
tial CKD in community-based individuals. One limitation of
the sample is that the eGFR was not measured directly, but
rather estimated from serum creatinine. Although these esti-
mations may be unreliable in obese people, we did not have
any significant differences between MCI subtypes and those
without MCI in BMI measures.5. Conclusion
The results from this study further emphasized the role
cognitive impairment plays in potential CKD development.
The association between poor eGFR and MCI is suggestive
of a pathway to VaD and/or AD; it seems that cognitive
impairment that is rooted in vascular pathology is not only a
risk factor for VaD but also for AD [35]. The association
that we found between decreased eGFR and aMCI and
dMCI illustrates how this may be true. Although it still is
not clear what links eGFR to MCI, vascular risk factors
seem to be playing a role. We urge researchers to further
investigate the eGFR-MCI association in relation to both
traditional risk factors, such as the roles of diabetes andhyper-
tension, and nontraditional risk factors, such as measuring
endothelial function, cerebral hemodynamics, white matter
hyperintensities, homocysteine levels, oxidative stress, and
inflammatory markers such as fibrinogen and C-reactive pro-
tein. If the association is attenuated, we may have some an-
swers as to what links eGFR to cognitive impairment.
Longitudinal investigations are also necessary to find out
the association between low eGFR/CKD and incident MCI
cases; further investigation into potential mediatory mecha-
nisms, such as the mentioned nontraditional risk factors
may also provide insight into causality. Although continuous
cognitive testing tomonitor changes is ideal in the early stages
of CKD, identifying risk factors that affect kidney and cogni-
tive function would help lead to preventative strategies of the
deterioration of thesemechanisms and also enhance interven-
tion plans for those already affected by disease.Acknowledgments
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1. Systematic review: For our literature search we
started by looking for keywords, such as “cognitive
function & CKD” in PubMed, and narrowed down
to research articles that specifically looked at kidney
function and mild cognitive impairment (MCI). We
also identified papers from articles we read.
2. Interpretation: Our results showed that decreased
estimated glomerular filtration rate (eGFR) is inde-
pendently associated with amnestic MCI (aMCI)
and dysexecutive MCI (dMCI). Two interpretations
seemed viable: (1) renal dysfunction may be causing
MCI or (2) renal dysfunction may be a marker of
vascular risk factors, such as the metabolic syndrome
or small vessel disease.
3. Future directions: We urge researchers to further
investigate the association between eGFR and MCI
in relation to both traditional and nontraditional
risk factors to find out what links eGFR to cognitive
impairment. Identifying cognitive impairment early
in potential chronic kidney disease development
may result in fewer complications and allow for
longer independent living, and subsequently less
hospitalizations.
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